Dermatology Clinic, University of Catania, Catania, Italy.
Expert Opin Emerg Drugs. 2021 Mar;26(1):27-38. doi: 10.1080/14728214.2021.1887138. Epub 2021 Feb 18.
: Rosacea is a common, chronic and relapsing inflammatory skin disease of the centrofacial area. Despite advancing knowledge on its pathogenesis, diagnosis, and treatment, some major unknowns still remain, including systematic evidence-based guidelines useful both for clinical assessment and therapeutic management. Topical treatment is regarded as a first-line option for mild to moderate rosacea and includes traditional and new FDA-approved prescription drugs, as well as off-label alternative topical agents.: Since improved awareness of rosacea pathogenetic mechanisms has led to the development of new potential therapeutic agents, a search was performed on the registry. The results identified several investigational topical drugs able to target one or more of the pathogenetic factors of rosacea.: The main unmet needs in the topical treatment of rosacea remain the management of vasomotor flushes and telangiectasias, as well as of troublesome symptoms such as burning and/or stinging. No single agent effective on all rosacea phenotypes is available so far, and preventive treatments capable of halting disease progression have not been identified yet. Finally, data on long-term efficacy and tolerability are still incomplete, especially for drugs more recently introduced in the market.
酒渣鼻是一种常见的、慢性的、复发性的中面部炎症性皮肤疾病。尽管人们对其发病机制、诊断和治疗有了更多的了解,但仍存在一些重大的未知因素,包括对临床评估和治疗管理都有用的基于系统的循证指南。局部治疗被认为是轻度至中度酒渣鼻的一线选择,包括传统的和新的获得 FDA 批准的处方药,以及非处方替代局部药物。
由于对酒渣鼻发病机制的认识提高,导致了新的潜在治疗药物的开发,因此在注册处进行了搜索。结果确定了几种有潜力的研究性局部药物,这些药物能够针对酒渣鼻的一种或多种发病因素。
酒渣鼻局部治疗的主要未满足需求仍然是管理血管舒缩性潮红和毛细血管扩张,以及处理烧灼感和/或刺痛等麻烦症状。到目前为止,还没有一种有效的药物能够针对所有酒渣鼻表型,也没有发现能够阻止疾病进展的预防性治疗方法。最后,关于长期疗效和耐受性的数据仍然不完整,特别是对于最近引入市场的药物。